Farletuzumab Ecteribulin: Optimizing Dosing to Mitigate Lung Toxicity While Targeting Folate Receptor Alpha in Advanced Cancers
Posted innews OB/GYN & Women's Health Oncology

Farletuzumab Ecteribulin: Optimizing Dosing to Mitigate Lung Toxicity While Targeting Folate Receptor Alpha in Advanced Cancers

This phase 1/2 study evaluates farletuzumab ecteribulin, a folate receptor alpha-targeting ADC, showing that fractionated dosing reduces interstitial lung disease risk and demonstrates preliminary antitumor activity in advanced ovarian, endometrial, triple-negative breast, and lung cancers.
Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial
Posted inClinical Updates news Oncology

Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial

A secondary analysis of the GAP70+ trial reveals that while 71.7% of older adults with advanced cancer prioritize quality of life, their clinical outcomes—including survival and toxicity—remain unchanged compared to those prioritizing survival, suggesting a systemic lack of responsiveness to patient goals.